[Results with the cytostatic agent bleomycin in tumour therapy (author's transl)].
D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use*; D001984:Bronchial Neoplasms / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002699:Chlorambucil / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004407:Dysgerminoma / Q000188:drug therapy; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009442:Neurilemmoma / Q000188:drug therapy; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D012075:Remission, Spontaneous; D014747:Vinblastine / Q000627:therapeutic use
D001761:Bleomycin; D002699:Chlorambucil; D014747:Vinblastine; D004317:Doxorubicin; D008727:Methotrexate
Ergebnisse mit dem Zytostatikum Bleomycin in der Tumortherapie.